1. Home
  2. COPR vs SCYX Comparison

COPR vs SCYX Comparison

Compare COPR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Copper Corporation Common Stock

COPR

Idaho Copper Corporation Common Stock

N/A

Current Price

$3.41

Market Cap

63.7M

Sector

N/A

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.95

Market Cap

51.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COPR
SCYX
Founded
N/A
1999
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.7M
51.4M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
COPR
SCYX
Price
$3.41
$4.95
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
93.8K
67.9K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
$609,174.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.05
$0.57
52 Week High
$4.16
$6.09

Technical Indicators

Market Signals
Indicator
COPR
SCYX
Relative Strength Index (RSI) 57.20 40.41
Support Level $2.49 $0.67
Resistance Level N/A $5.56
Average True Range (ATR) 0.31 0.35
MACD 0.05 -0.10
Stochastic Oscillator 68.66 0.00

Price Performance

Historical Comparison
COPR
SCYX

About COPR Idaho Copper Corporation Common Stock

Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: